As Expected, Quest Diagnostics Posts 2 Percent Sales Decline | GenomeWeb

NEW YORK (GenomeWeb News) – Quest Diagnostics today reported that its third quarter sales were down 2 percent year over year, in line with its pre-announcement made just last week.

The clinical lab and diagnostic information services provider reported revenues of $1.79 billion for the three months ended Sept. 30, down 2 percent year over year from $1.82 billion. Analysts had previously expected $1.84 billion in revenues for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.